Based on the key indicators related to Enlivex Therapeutics' liquidity, profitability, solvency, and operating efficiency, Enlivex Therapeutics is not in a good financial situation at the present time. It has a very high chance of going through financial crunch in December. At this time, Enlivex Therapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year. Other Stockholder Equity is likely to climb to about 145.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.6 M in 2024. Key indicators impacting Enlivex Therapeutics' financial strength include:
Investors should never underestimate Enlivex Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Enlivex Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Enlivex Therapeutics.
Net Income
(27.61 Million)
Enlivex
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Capital Expenditures
Total Cash From Financing Activities
Change To Liabilities
Other Cashflows From Investing Activities
Change To Account Receivables
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Total Cash From Operating Activities
Net Income
End Period Cash Flow
Begin Period Cash Flow
Other Non Cash Items
Sale Purchase Of Stock
Depreciation
Investments
Change To Operating Activities
Change To Netincome
Change To Inventory
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Accounts Payable
Cash
Other Assets
Short Term Investments
Other Current Assets
Total Liab
Intangible Assets
Common Stock
Property Plant Equipment
Long Term Debt
Good Will
Preferred Stock Total Equity
Other Liab
Net Debt
Retained Earnings
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Current Assets
Property Plant And Equipment Net
Non Current Assets Total
Non Currrent Assets Other
Property Plant And Equipment Gross
Capital Surpluse
Accumulated Other Comprehensive Income
Non Current Liabilities Total
Net Tangible Assets
Net Invested Capital
Net Working Capital
Capital Stock
Short Long Term Debt Total
Capital Lease Obligations
Inventory
Non Current Liabilities Other
Short Term Debt
Interest Expense
Research Development
Cost Of Revenue
Selling General Administrative
Gross Profit
Income Tax Expense
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Depreciation And Amortization
Selling And Marketing Expenses
Tax Provision
Net Interest Income
Interest Income
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Enlivex Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Enlivex Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Enlivex Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Enlivex Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Enlivex Therapeutics. Check Enlivex Therapeutics' Beneish M Score to see the likelihood of Enlivex Therapeutics' management manipulating its earnings.
Enlivex Therapeutics Stock Summary
Enlivex Therapeutics competes with Pluri, BioLineRx, Purple Biotech, Pmv Pharmaceuticals, and Aptevo Therapeutics. Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel. Enlivex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 71 people.
Enlivex Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Enlivex Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Enlivex Therapeutics's current stock value. Our valuation model uses many indicators to compare Enlivex Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Enlivex Therapeutics competition to find correlations between indicators driving Enlivex Therapeutics's intrinsic value. More Info.
Enlivex Therapeutics is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . At this time, Enlivex Therapeutics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Enlivex Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Enlivex Therapeutics Systematic Risk
Enlivex Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Enlivex Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Enlivex Therapeutics correlated with the market. If Beta is less than 0 Enlivex Therapeutics generally moves in the opposite direction as compared to the market. If Enlivex Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Enlivex Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Enlivex Therapeutics is generally in the same direction as the market. If Beta > 1 Enlivex Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Enlivex Therapeutics Thematic Clasifications
Enlivex Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Enlivex Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Enlivex Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Enlivex Therapeutics growth as a starting point in their analysis.
Enlivex Therapeutics November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Enlivex Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Enlivex Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Enlivex Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Enlivex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Enlivex Therapeutics's daily price indicators and compare them against related drivers.
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.